Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (741-750 of 869) with videos related to

Pageof 87
Sort By:
Blood|March 19, 2020
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myelomaYan Xu, Mariateresa Fulciniti, Mehmet K Samur, et al.
Blood|May 22, 2025
CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAsEugenio Morelli, Anil Aktas-Samur, Domenico Maisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple MyelomaEugenio Morelli, Caroline Fidalgo Ribeiro, Silvia D Rodrigues, et al.
Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.
Blood|March 23, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupPieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The New England Journal of Medicine|August 30, 2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
American Journal of Hematology|February 19, 2019
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk groupMark Bustoros, Efstathios Kastritis, Romanos Sklavenitis-Pistofidis, et al.
Pageof 87

Showing results (741-750 of 869) with videos related to

Sort By:
Pageof 87
Blood|March 19, 2020
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myelomaYan Xu, Mariateresa Fulciniti, Mehmet K Samur, et al.
Blood|May 22, 2025
CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAsEugenio Morelli, Anil Aktas-Samur, Domenico Maisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple MyelomaEugenio Morelli, Caroline Fidalgo Ribeiro, Silvia D Rodrigues, et al.
Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.
Blood|March 23, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupPieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The New England Journal of Medicine|August 30, 2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
American Journal of Hematology|February 19, 2019
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk groupMark Bustoros, Efstathios Kastritis, Romanos Sklavenitis-Pistofidis, et al.
Pageof 87